Histone Deacetylase Inhibitor LAQ824 Augments Inflammatory Responses in Macrophages Through Transcriptional Regulation of IL-10

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2011 Mar 4

PMID 21368229

Citations 31

Authors

Hongwei Wang

Fengdong Cheng

Karrune Woan

Eva Sahakian

Oscar Merino

Jennifer Rock-Klotz

Ildefonso Vicente-Suarez

Javier Pinilla-Ibarz

Kenneth L Wright

Edward Seto

Kapil Bhalla

Alejandro Villagra

Eduardo M Sotomayor

Affiliations

Soon will be listed here.

Abstract

APCs are important in the initiation of productive Ag-specific T cell responses and the induction of T cell anergy. The inflammatory status of the APC at the time of encounter with Ag-specific T cells plays a central role in determining such divergent T cell outcomes. A better understanding of the regulation of proinflammatory and anti-inflammatory genes in its natural setting, the chromatin substrate, might provide novel insights to overcome anergic mechanisms mediated by APCs. In this study, we show for the first time, to our knowledge, that treatment of BALB/c murine macrophages with the histone deacetylase inhibitor LAQ824 induces chromatin changes at the level of the IL-10 gene promoter that lead to enhanced recruitment of the transcriptional repressors HDAC11 and PU.1. Such an effect is associated with diminished IL-10 production and induction of inflammatory cells able of priming naive Ag-specific T cells, but more importantly, capable of restoring the responsiveness of anergized Ag-specific CD4(+) T cells.

Citing Articles

Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors.

Ibrahim M, Zheng H, Barlow M, Latif Y, Chen Z, Yu X J Immunol. 2024; 212(4):737-747.

PMID: 38169329 PMC: 10872871. DOI: 10.4049/jimmunol.2300475.

Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice.

Melica M, Antonelli G, Semeraro R, Angelotti M, Lugli G, Landini S Sci Transl Med. 2022; 14(657):eabg3277.

PMID: 35947676 PMC: 7614034. DOI: 10.1126/scitranslmed.abg3277.

CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.

Chen J, Chou C, Wu Y, Yang M, Chu S, Chao Y Sci Rep. 2022; 12(1):1100.

PMID: 35058524 PMC: 8776878. DOI: 10.1038/s41598-022-05055-8.

Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.

Gracia-Hernandez M, Munoz Z, Villagra A Cancers (Basel). 2021; 13(24).

PMID: 34944799 PMC: 8699560. DOI: 10.3390/cancers13246180.

Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.

Zhang S, Zhan L, Li X, Yang Z, Luo Y, Zhao H Int J Biol Sci. 2021; 17(13):3381-3400.

PMID: 34512154 PMC: 8416716. DOI: 10.7150/ijbs.62001.

References

Saraiva M, OGarra A . The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010; 10(3):170-81. DOI: 10.1038/nri2711. View

Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D . Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1998; 95(3):1178-83. PMC: 18712. DOI: 10.1073/pnas.95.3.1178. View

Reddy P, Maeda Y, Hotary K, Liu C, Reznikov L, Dinarello C . Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004; 101(11):3921-6. PMC: 374345. DOI: 10.1073/pnas.0400380101. View

Kirberg J, Baron A, Jakob S, Rolink A, Karjalainen K, von Boehmer H . Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med. 1994; 180(1):25-34. PMC: 2191558. DOI: 10.1084/jem.180.1.25. View

Yao Y, Li W, Kaplan M, Chang C . Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med. 2005; 201(12):1899-903. PMC: 2212025. DOI: 10.1084/jem.20050324. View

Horna P, Sotomayor E . Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets. 2007; 7(1):41-53. DOI: 10.2174/156800907780006940. View

Sotomayor E, Fu Y, Lopez-Cepero M, Herbert L, Jimenez J, Albarracin C . Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol. 1991; 147(8):2816-23. View

OConnor O, Heaney M, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B . Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2005; 24(1):166-73. DOI: 10.1200/JCO.2005.01.9679. View

Foster S, Hargreaves D, Medzhitov R . Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007; 447(7147):972-8. DOI: 10.1038/nature05836. View

10.

Rubtsov Y, Rasmussen J, Chi E, Fontenot J, Castelli L, Ye X . Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28(4):546-58. DOI: 10.1016/j.immuni.2008.02.017. View

11.

Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle F . Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 2004; 165(6):1853-63. PMC: 1618726. DOI: 10.1016/S0002-9440(10)63238-5. View

12.

Tone M, Powell M, Tone Y, Thompson S, Waldmann H . IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol. 2000; 165(1):286-91. DOI: 10.4049/jimmunol.165.1.286. View

13.

Groux H, Bigler M, De Vries J, Roncarolo M . Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996; 184(1):19-29. PMC: 2192687. DOI: 10.1084/jem.184.1.19. View

14.

Steinman R, Hawiger D, Nussenzweig M . Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. DOI: 10.1146/annurev.immunol.21.120601.141040. View

15.

Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S . Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20:621-67. DOI: 10.1146/annurev.immunol.20.100301.064828. View

16.

Benkhart E, Siedlar M, Wedel A, Werner T . Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J Immunol. 2000; 165(3):1612-7. DOI: 10.4049/jimmunol.165.3.1612. View

17.

Sotomayor E, Borrello I, Rattis F, Cuenca A, Abrams J, Levitsky H . Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001; 98(4):1070-7. DOI: 10.1182/blood.v98.4.1070. View

18.

Evel-Kabler K, Song X, Aldrich M, Huang X, Chen S . SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest. 2005; 116(1):90-100. PMC: 1312019. DOI: 10.1172/JCI26169. View

19.

Vicente-Suarez I, Takahashi Y, Cheng F, Horna P, Wang H, Wang H . Identification of a novel negative role of flagellin in regulating IL-10 production. Eur J Immunol. 2007; 37(11):3164-75. DOI: 10.1002/eji.200737306. View

20.

Zhang X, Edwards J, Mosser D . Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol. 2006; 177(2):1282-8. PMC: 2643023. DOI: 10.4049/jimmunol.177.2.1282. View